Cardinal has been contacted by the Federal Trade Commission for information on the drug wholesale market related to the proposed merger of AmeriSource and Bergen Brunswig, CEO Robert Walter says. "We're certainly obligated to respond and will respond with the appropriate information," he says. "We're not taking a public position on this merger," Walter adds. "I don't frankly think the FTC is interested in our opinion about it as a competitor. I think they're interested in knowing more about the market, and we'll participate fully"
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth